Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.

This article reviews androgenetic alopecia and its effects but reports no new clinical results, highlighting that current treatments offer only temporary therapeutic benefits.

This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.

This study found a significant correlation between aerobic and anaerobic bacteria in the scalp microbiome and female androgenetic alopecia, with notable prevalence differences in specific bacterial groups between affected and non-affected women.

This study reports that a novel nanolipogel with moderate rigidity (NLG-2.5) enhances transdermal delivery of fucosterol, displaying superior permeability, targeting hair follicles, and promoting hair growth in androgenetic alopecia model mice by inhibiting inflammation and androgen pathways and promoting angiogenesis.

This study reported significant improvements in hair density and growth ratio in androgenetic alopecia patients receiving concentrated growth factor injections, with benefits sustained for 6 months.

This study found that recombinant human FGF9 expressed in Arabidopsis thaliana oil bodies significantly promoted the proliferation of NIH/3T3 cells.

This study suggests that finasteride may inhibit testosterone-induced expression of TGF-beta1 and type I procollagen, potentially explaining its role in preventing perifollicular fibrosis in androgenetic alopecia.

This study found that iontophoresis with growth factor cocktail including fibroblast growth factor 5-short significantly increased hair density in patients with androgenetic alopecia over 24 weeks.

This study found that FUE megasession with a specific surgical design is an effective and satisfactory treatment for Asian patients with high-grade male androgenetic alopecia, achieving natural hair density and high patient and doctor satisfaction, with minimal side effects.

This research suggests that testosterone-induced expression of TGF-beta1 and type I procollagen may lead to perifollicular fibrosis in androgenetic alopecia, with finasteride inhibiting this process as a possible mechanism for its effects.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

This article discusses approaches to diagnosing and treating androgenetic alopecia but reports no new clinical results.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

In this study, researchers reviewed cases of EGFR inhibitor-induced folliculitis decalvans and reported the first known occurrences associated with afatinib in three female NSCLC patients, highlighting the importance of early diagnosis and management to improve patient quality of life.

In this study, trichoscopy was used to diagnose female androgenic alopecia with 92% specificity by identifying specific hair and scalp patterns.

Adding a cosmetic gel with caffeine, taurine, and growth factors to standard hair loss treatments could improve results.

The Fas/FasL pathway may play a role in alopecia areata.

The researchers reported that adenosine increases FGF-7 expression in dermal papilla cells, which may stimulate hair growth via the A2b adenosine receptor and cAMP pathway.

This paper introduces Concentration Growth Factor (CGF) as a potential treatment for androgenetic alopecia, but reports no clinical findings on its effectiveness in promoting hair growth.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

This study found that FGF21 suppresses inflammation induced by C. acnes in both human skin cells and mouse models, suggesting potential use in acne treatment.

This study found that oral finasteride improved hair growth and reduced hair shedding in male patients with androgenetic alopecia, with no significant side effects observed.

This article discusses a potential link between adipocyte-myofibroblast transition and androgenetic alopecia, suggesting AMT may play a role in fibrosis associated with the condition but presents no new results.

This article discusses various treatments for androgenetic alopecia and reports no new clinical results, noting the condition's aesthetic and psychological impact.

This article reviews the general, pathophysiological, diagnostic, and therapeutic aspects of alopecia frontal fibrosante, highlighting its irreversible nature and the importance of early diagnosis, but it reports no new clinical results.

This study found that trichoscopy criteria can distinguish female androgenic alopecia from chronic telogen effluvium, with specific features achieving 98% diagnostic specificity.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.